# EDIT — local-model

## Metadata

ticker: EDIT
arm: local-model
judge_prompt_version: v2
context_sha256: 35fd11f194201b563e370554975b823c3e44bf58552a16df1b8ce296004ac7c4
local_model_served_name: financial-lora
local_model_dir: qwen-ft
local_model_backend: openai
local_model_url: http://vllm.financial-agent.svc:8000
local_model_sampling: {"max_tokens": 512, "min_p": 0.0, "repetition_penalty": 1.1, "temperature": 0.1, "top_k": 20, "top_p": 0.8}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.69,
  "currency": "USD",
  "market_cap": 413130304.0,
  "forward_pe": -3.5717604,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from EDIT's SEC Filings

## Financial Position and Losses
- The company has accumulated significant operating losses totaling $1.6 billion as of December 31, 2025
- Net losses were $160.1 million (2025), $237.1 million (2024), and $153.2 million (2023)
- The company expects to continue incurring significant losses for the foreseeable future

## Funding and Capital Requirements
- Current cash and equivalents are projected to fund operations into Q3 2027
- Substantial additional funding will be needed to continue operations and advance product development
- Primary funding sources include public equity offerings, debt financing, collaborations, and licensing arrangements
- Limited committed external funding sources exist, with contingent payments from BMS collaboration and Vertex license agreement being the only significant committed potential sources

## Development Stage and Timeline
- The company is currently in preclinical testing stages for its most advanced research programs
- EDIT-401 is a key product candidate requiring continued development
- Commercial revenues are not expected for years, if at all
- Profitability achievement and sustainability remain uncertain

## Risk Factors
- Inability to raise capital when needed could force delays or elimination of research and development programs
- Economic downturns or unfavorable political developments could impact the ability to raise capital and maintain operations
- Regulatory requirements could increase expenses beyond current expectations
- Success depends on completing preclinical studies, clinical trials, obtaining regulatory approval, and achieving commercial success

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the main categories being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has incurred net losses of $160.1 million, $237.1 million, and $153.2 million for 2025, 2024, and 2023 respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Significant funding requirements**: Substantial additional capital will be needed to continue operations, with existing cash expected to fund operations only into the third quarter of 2027.
- **Limited external funding sources**: The company has limited committed potential external sources of funds beyond contingent payments from collaboration agreements.

## Development and Commercialization Challenges
- **Early-stage development**: The company is currently only in preclinical testing stages for its most advanced research programs.
- **Time and expense intensive process**: Identifying product candidates and conducting preclinical testing and clinical trials is time-consuming, expensive, and uncertain, taking years to complete.
- **No guarantee of success**: The company may never generate necessary data or results required to obtain marketing approval and achieve product sales.
- **Years to commercialization**: Commercial revenues are not expected for years, if at all.

## Economic and Regulatory Risks
- **Economic sensitivity**: Unfavorable national or global economic conditions or political developments could adversely affect the business, including weakened demand for products and difficulty raising capital.
- **Regulatory uncertainty**: Regulatory authorities may require additional clinical and other studies beyond those currently anticipated.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc., trades under the ticker EDIT. It's headquartered in Cambridge, Massachusetts. As of March 9, 2026, it carries a current stock price of $2.69 per share in the United States dollars (USD). It currently holds a market capitalization of $41.3 billion in the USD currency. Its most recent closing price was $2.69 per share. It carries a week 52 high of $4.54 per share and a week 52 low of $1.66 per share. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year. It reports net income of -$7.4 billion over the past year

### Recent Developments

Editas Medicine continues to face significant financial headwinds, with the company reporting a net loss of $73.9 million against minimal revenue of $47 million, reflecting the substantial R&D investments required for gene-editing therapeutics development. The stock has declined substantially from its 52-week high of $4.54 to $2.69, indicating investor concerns about the company's path to profitability and capital requirements. Recent SEC filings highlight ongoing risks related to the company's financial position and need for additional capital, which remains a critical concern for shareholders. With a negative profit margin of -157% and a market cap of approximately $413 million, Editas is at an inflection point where clinical trial progress and potential regulatory approvals will be essential to validate its gene-editing platform and justify continued investor support.

### SEC Filing Highlights

Editas Medicine faces significant financial headwinds with accumulated operating losses of $1.6 billion and net losses of $160.1 million in 2025, with the company expecting continued substantial losses for the foreseeable future. Current cash reserves are projected to fund operations only through Q3 2027, necessitating additional capital raises through equity offerings, debt financing, or strategic partnerships to sustain development efforts. The company remains in early-stage development with EDIT-401 as a key candidate, with commercial revenues not anticipated for years and profitability uncertain. Critical risks include dependence on external funding availability, regulatory approval uncertainties, and the inherent challenges of advancing gene-editing therapies through preclinical and clinical development. Limited committed funding sources exist beyond contingent payments from existing collaborations with BMS and Vertex.

### Risk Factors Disclosed

The company faces several significant risks that could have material adverse effects on its business, financial condition, results of operations, and prospects. These risks include but are not limited to:

#### Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has incurred net losses of $160.1 million, $237.1 million, and $153.2 million for 2025, 2024, and 2023 respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Significant funding requirements**: Substantial additional capital will be needed to continue operations, with existing cash expected to fund operations only into the third quarter of 2027.
- **Limited external funding sources**: The company has limited committed potential external sources of funds beyond contingent payments from collaboration agreements.

#### Development and Commercialization Challenges
- **Early-stage development**: The company is currently only in preclinical testing stages for its most advanced research programs.
- **Time and expense intensive process**: Identifying product candidates and conducting preclinical testing and clinical trials is time-consuming, expensive, and uncertain, taking years to complete.
- **No guarantee of success**: The company may never generate necessary data or results required to obtain marketing approval and achieve product sales.
- **Years to commercialization**: Commercial revenues are not expected for years, if at all.

#### Economic and Regulatory Risks
- **Economic sensitivity**: Unfavorable national or global economic conditions or political developments could adversely affect the business, including weakened demand for products and difficulty raising capital.
- **Regulatory uncertainty**: Regulatory authorities may require additional clinical and other studies beyond those currently anticipated.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a Cambridge, Massachusetts-based gene-editing therapeutics company operating at an early stage of development, with its most advanced candidate, EDIT-401, still in preclinical testing and commercial revenues not anticipated for years. Trading at $2.69 per share — well off its 52-week high of $4.54 and carrying an accumulated deficit of $1.6 billion — the stock reflects deep investor skepticism about the company's path to profitability, particularly given that existing cash is projected to fund operations only through Q3 2027. The single most important near-term variable is whether Editas can secure sufficient additional capital — through equity offerings, debt financing, or expanded strategic partnerships — before its current runway expires, as failure to do so would materially threaten the company's ability to continue advancing its pipeline.

### Outlook
The directional outlook for Editas Medicine is cautious. The company's cash runway extending only through Q3 2027 creates an urgent and overriding constraint that will likely dominate the near-term narrative regardless of scientific progress, making the terms and timing of any future capital raise the most critical variable for investors to monitor. On the headwind side, the combination of early-stage development, a deeply negative profit margin, a sustained decline from the 52-week high, and the absence of committed external funding beyond contingent collaboration payments from BMS and Vertex leaves the company with limited margin for error; any deterioration in capital markets conditions or unfavorable macroeconomic developments could meaningfully compress the company's ability to raise funds on acceptable terms. On the tailwind side, positive preclinical or early clinical data from EDIT-401, a meaningful expansion of existing collaboration agreements, or a new strategic partnership could materially strengthen the thesis by extending the runway and validating the gene-editing platform. Investors should watch the pace and quality of EDIT-401 development updates, any announcements related to equity or debt financing, and the evolution of the BMS and Vertex collaboration arrangements as the clearest leading indicators of whether the company's position is stabilizing or deteriorating. A shift to a more constructive view would require demonstrated progress toward clinical milestones paired with a credible, near-term solution to the capital gap; absent those developments, the risk profile remains elevated.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "Trading at $2.69 per share"
LABEL: SUPPORTED
REASON: The raw source data lists current_price as 2.69 USD, and the pre-written sections confirm "$2.69 per share."

---

CLAIM: "well off its 52-week high of $4.54"
LABEL: SUPPORTED
REASON: The raw source data lists week_52_high as 4.537, which rounds to $4.54 as stated in the pre-written "Recent Developments" section; arithmetic confirms $2.69 is well below $4.54.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and Risk Factors sections explicitly state "accumulated deficit of $1.6 billion as of December 31, 2025."

---

CLAIM: "existing cash is projected to fund operations only through Q3 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both state "existing cash expected to fund operations only into the third quarter of 2027."

---

CLAIM: "EDIT-401, still in preclinical testing"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "The company is currently in preclinical testing stages for its most advanced research programs" and names EDIT-401 as a key product candidate; the SEC Filing Highlights pre-written section confirms this directly.

---

CLAIM: "commercial revenues not anticipated for years"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both state "Commercial revenues are not expected for years, if at all."

---

**OUTLOOK**

---

CLAIM: "cash runway extending only through Q3 2027"
LABEL: SUPPORTED
REASON: Directly stated in both RAG sections: "existing cash expected to fund operations only into the third quarter of 2027."

---

CLAIM: "a deeply negative profit margin"
LABEL: SUPPORTED
REASON: The raw source data lists profit_margin as -1.57322 (i.e., approximately -157%), and the pre-written "Recent Developments" section explicitly states "a negative profit margin of -157%"; the claim's directional characterization ("deeply negative") is arithmetically verified.

---

CLAIM: "a sustained decline from the 52-week high"
LABEL: SUPPORTED
REASON: Current price $2.69 vs. 52-week high $4.537 represents a decline of approximately 40.7%, confirming a sustained decline; both figures are present in the raw source data.

---

CLAIM: "absence of committed external funding beyond contingent collaboration payments from BMS and Vertex"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "contingent payments from BMS collaboration and Vertex license agreement being the only significant committed potential sources," and the Risk Factors section confirms "limited committed potential external sources of funds beyond contingent payments from collaboration agreements"; BMS and Vertex are named explicitly in the pre-written SEC Filing Highlights section.

---

CLAIM: "positive preclinical or early clinical data from EDIT-401"
LABEL: SUPPORTED
REASON: EDIT-401 is named as a key product candidate in the RAG SEC Highlights and the pre-written SEC Filing Highlights; the claim that it is in preclinical stages (with potential for early clinical data as a forward-looking watch item) is consistent with the source data characterizing it as a preclinical-stage candidate.

---

CLAIM: "evolution of the BMS and Vertex collaboration arrangements"
LABEL: SUPPORTED
REASON: Both BMS and Vertex are explicitly named in the RAG SEC Highlights ("contingent payments from BMS collaboration and Vertex license agreement") and the pre-written SEC Filing Highlights section.

---

**SUMMARY OF FLAGS**

No claims in the Executive Summary or Outlook are found to be UNSUPPORTED or INFERENCE-only. All quantitative figures, named entities, milestones, and forward-looking thresholds are directly traceable to the raw source data or pre-written sections, and all applicable arithmetic checks (price vs. 52-week high, profit margin sign and magnitude, runway date) confirm the stated values. The one notable data quality issue in the pre-written "Financial Health" section — where market cap is erroneously stated as "$41.3 billion" and net income as "-$7.4 billion" rather than the correct ~$413 million and ~-$73.9 million from the raw data — does **not** propagate into the Executive Summary or Outlook, which correctly use the figures from the "Recent Developments" and SEC sections instead.
